Jump to content
  • #RQA2020 Virtual Conference - Early Bird Pricing Now Available

    More Information
  • We are now offering Remote Courses

    Equal benefits to our residential courses, without the travel.

    View Courses
  • Newsletter

    Non-members can signup to keep up to date with RQA news and events.

    Add your details now

*Please note that while still operational, the RQA office is being run remotely, so please bear with us if we take a little longer than usual to deal with any queries*

Who are RQA

The Research Quality Association (RQA) is a professional membership body dedicated to informing and advancing its members. We provide status and visibility for individuals engaged in the quality of research concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since our inception in 1977, the Association has increased and evolved to reflect regulatory changes, the growing impact of regulatory inspection and the ever-changing structure and needs of industry. RQA's purpose is to drive quality and integrity in scientific research.  

Read more+

Our vision

To inspire quality, integrity and compliance in scientific research.

Our mission

To provide knowledge and learning in the scientific research community by building expertise through training, communication, engagement and collaboration.

Newsletter

Sign up to the latest news and events.

Latest News

View all news

Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 – update #3

As part of its coordinated response to the pandemic, the International Coalition of Medicines Regulatory Authorities (ICMRA) convened its regular high-level meeting of regulators from around the world on 27 May 2020 to discuss COVID-19 policies, regulatory aspects of COVID-19 medicine development and pragmatic approaches to address challenges posed by the ongoing pandemic.

Read more+

MHRA issues a scientific opinion for the first medicine to treat COVID-19 in the UK

MHRA has today given the first positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for use of Gilead’s remdesivir.

Read more+

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020

Eight new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its May 2020 meeting.

Read more+